Dimethyl-(oxiran-2-ylmethyl)-[3-(prop-2-enoylamino)propyl]azanium
C11H21N2O2+ — CID 87225557
Data last refreshed: (MolForge compound catalog, from PubChem)
About Dimethyl-(oxiran-2-ylmethyl)-[3-(prop-2-enoylamino)propyl]azanium
Dimethyl-(oxiran-2-ylmethyl)-[3-(prop-2-enoylamino)propyl]azanium (PubChem CID 87225557) has the molecular formula C11H21N2O2+ and a molecular weight of 213.30 g/mol. Its IUPAC name is dimethyl-(oxiran-2-ylmethyl)-[3-(prop-2-enoylamino)propyl]azanium.
Molecular Properties
| Compound Name | Dimethyl-(oxiran-2-ylmethyl)-[3-(prop-2-enoylamino)propyl]azanium |
|---|---|
| PubChem CID | 87225557 |
| Molecular Formula | C11H21N2O2+ |
| Molecular Weight | 213.30 g/mol |
| Exact Mass | 213.16 |
| IUPAC Name | dimethyl-(oxiran-2-ylmethyl)-[3-(prop-2-enoylamino)propyl]azanium |
| SMILES | C=CC(=O)NCCC[N+](C)(C)CC1CO1 |
| InChI | InChI=1S/C11H20N2O2/c1-4-11(14)12-6-5-7-13(2,3)8-10-9-15-10/h4,10H,1,5-9H2,2-3H3/p+1 |
| InChIKey | AZKPQQKTYCGFBG-UHFFFAOYSA-O |
| XLogP | 0.15 |
| TPSA | 41.63 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 2 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 15 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 213.30 |
| LogP ≤ 5 | 0.15 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 2 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'}, {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'}, {'alert_name': 'quaternary_nitrogen_2', 'substructure': 'N/A'}, {'alert_name': 'Three-membered_heterocycle', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 87225557 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.